On January 10, Johnson & Johnson announced that it would join the price increase army and focus on raising the prices of more than 20 prescription drugs, including the psoriasis drug Stelara, the prostate cancer drug Zytiga, and the anticoagulant Xarelto.According to Rx Savings Solutions data, Johnson's prescription drug growth is between 6% and 7%.
On the day Johnson & Johnson announced price increases, members of the Democratic Party of the United States Congress just submitted a bill to lower the price of prescription drugs for US consumers.
Johnson & Johnson said that the average price of all its drugs sold in 2019 was higher than in 2018 4.2%, but the average net price actually drops.Because companies usually negotiate with the paying party to determine a reimbursement or discount to expand patient coverage.Johnson & Johnson also said that the pricing of other drugs will not be increased in 2019.
US drug prices started with a general increase in 2019.As of January 2, more than 250 prescription drugs in the United States announced price increases.As of January 10, there were close to 490 prescription drugs announced price increases, including Sanofi's insulin price hike 4.4% ~ 5.2%, Novo Nordisk's insulin price increase 4.9%.Novo Nordisk said the increase was to compensate for discounts or refunds to insurers and pharmacy welfare agencies.
In fact, under the pressure of lawyers and President Trump, the price increase of prescription drugs in the United States in 2019 was weaker than in 2018.In the first 10 days of 2018, a total of 650 prescription drugs in the United States announced price increases.
The United States is a pharmaceutical market that allows pharmaceutical companies to set their own prices.The price of drugs in the United States is usually higher than in other countries that control drug prices directly or indirectly.The U.S. Department of Health and Human Services has introduced a policy that expects to lower drug prices, hoping that patients can enjoy more discounts negotiated between Medicare payers and companies.